Cross-protective immunity to influenza A viruses (Q30396399)

21 June 2017

title

Cross-protective immunity to influenza A viruses (English)

1 reference

21 June 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21087110

29 August 2024

Suzanne L. Epstein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21087110

29 August 2024

Graeme E. Price

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21087110

29 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21087110

29 August 2024

publication date

1 November 2010

1 reference

full work available at URL

21 June 2017

http://www.future-drugs.com/doi/abs/10.1586/erv.10.123

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21087110

http://www.tandfonline.com/doi/pdf/10.1586/erv.10.123

29 August 2024

1 reference

Expert Review of Vaccines

29 August 2024

published in

1 reference

21 June 2017

1 reference

21 June 2017

1 reference

21 June 2017

page(s)

1325-1341

1 reference

A novel influenza A virus mitochondrial protein that induces cell death.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Control of influenza virus infection by immunity to conserved viral features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Influenza vaccine: the challenge of antigenic drift.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Heterosubtypic immunity to influenza A virus: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Virus-specific CD8+ T cells in primary and secondary influenza pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Immunity to influenza in ferrets. VII. Effect of previous infection with heterotypic and heterologous influenza viruses on the response of ferrets to inactivated influenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Highly pathogenic avian influenza virus infection of mallards with homo- and heterosubtypic immunity induced by low pathogenic avian influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Functional significance of the perforin/granzyme cell death pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Resistance to and Recovery from Lethal Influenza Virus Infection in B Lymphocyte–deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Induction of heterosubtypic immunity to influenza virus by intranasal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Functionally distinct T cells in three compartments of the respiratory tract after influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Rapid effector function in CD8+ memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Time lines of infection and disease in human influenza: a review of volunteer challenge studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Cytotoxic T-cell immunity to influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Declining T-cell immunity to influenza, 1977-82

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Comparison of multiple vaccine vectors in a single heterologous prime-boost trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Live attenuated versus inactivated influenza vaccine in infants and young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Comparative efficacy of inactivated and live attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

DNA Immunization for Influenza Virus: Studies Using Hemagglutinin‐ and Nucleoprotein‐Expressing DNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Viruses as vaccine vectors for infectious diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Human memory CTL response specific for influenza A virus is broad and multispecific

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Ab and T cell epitopes of influenza A virus, knowledge and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

A universal epitope-based influenza vaccine and its efficacy against H5N1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Association of serum anti-neuraminidase antibody with resistance to influenza in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

M2e-based universal influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Repeated influenza vaccination of healthy children and adults: borrow now, pay later?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Attenuating mutations of the matrix gene of influenza A/WSN/33 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Influenza A virus lacking M2 protein as a live attenuated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Modified M2 proteins produce heterotypic immunity against influenza A virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Improved design and intranasal delivery of an M2e-based human influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Epitope-based vaccine against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

Yearly influenza vaccinations: a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.123

INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

21 January 2018

1 reference

Lessons for human influenza from pathogenicity studies with ferrets

29 August 2024

1 reference

Evidence of a cross-protective immune response to influenza A in the cotton rat model

29 August 2024

1 reference

Respiratory and systemic humoral and cellular immune responses of pigs to a heterosubtypic influenza A virus infection

29 August 2024

1 reference

Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells

29 August 2024

1 reference

Clearance of an Influenza A Virus by CD4+T Cells Is Inefficient in the Absence of B Cells

29 August 2024

1 reference

β2-microglobulin-deficient mice demonstrate class II MHC restricted anti-viral CD4+ but not CD8+ CTL against influenza-sensitized autologous splenocytes

29 August 2024

1 reference

Immune CD4+ T cells promote the clearance of influenza virus from major histocompatibility complex class II -/- respiratory epithelium

29 August 2024

1 reference

CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch

29 August 2024

1 reference

Studies in experimental immunology of influenza. IV. The protective value of active immunization

29 August 2024

1 reference

Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic.

29 August 2024

1 reference

Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections

29 August 2024

1 reference

Genetic control of immune responses to influenza A matrix 2 protein (M2)

29 August 2024

1 reference

Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children

29 August 2024

1 reference

Individuals infected with two subtypes of influenza A virus in the same season

29 August 2024

1 reference

Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses

29 August 2024

1 reference

Temperature-Sensitive Mutants of Influenza Virus. III. Further Characterization of the ts-1[E] Influenza A Recombinant (H3N2) Virus in Man

29 August 2024

1 reference

Journal of Clinical Investigation

29 August 2024

118

3478

Lee

2008

1 reference

Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus

29 August 2024

1 reference

Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies

29 August 2024

1 reference

Class I MHC molecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T cells

29 August 2024

1 reference

Vaccination with an acidic polymerase epitope of influenza virus elicits a potent antiviral T cell response but delayed clearance of an influenza virus challenge

29 August 2024

1 reference

A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice

29 August 2024

1 reference

A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains

29 August 2024

102

1 reference

Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions

29 August 2024

104

1 reference

A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery

29 August 2024

117

1 reference

T cell responses are better correlates of vaccine protection in the elderly

29 August 2024

130

1 reference

H1N1: can a pandemic cycle be broken?

29 August 2024

137

1 reference

Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens

29 August 2024

139

1 reference

Homotypic and heterotypic immunity of influenza A viruses induced by recombinants of the cold-adapted master strain A/Ann Arbor/6/60-ca

29 August 2024

140

1 reference

Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus

29 August 2024

141

1 reference

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

29 August 2024

148

1 reference

29 August 2024

Identifiers

DOI

10.1586/ERV.10.123

1 reference

21 June 2017

1 reference